Novel therapeutic agents in clinical development for systemic lupus erythematosus

Conventional immunosuppressive therapies have radically transformed patient survival in systemic lupus erythematosus (SLE), but their use is associated with considerable toxicity and a substantial proportion of patients remain refractory to treatment. A more comprehensive understanding of the comple...

Descripción completa

Detalles Bibliográficos
Autores principales: Jordan, Natasha, Lutalo, Pamela MK, D’Cruz, David P
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2013
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3667088/
https://www.ncbi.nlm.nih.gov/pubmed/23642011
http://dx.doi.org/10.1186/1741-7015-11-120

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3667088/
https://www.ncbi.nlm.nih.gov/pubmed/23642011
http://dx.doi.org/10.1186/1741-7015-11-120

Ejemplares similares